The role of the plasminogen activation system in angiogenesis and metastasis

Surgical Oncology Clinics of North America

Volumn 10, Issue 2, 2001, Pages 393-415

  Rabbani, S A ^a   Mazar, A P ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; GROWTH FACTOR; INTEGRIN; MATRIX METALLOPROTEINASE; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ANGIOGENESIS; BASEMENT MEMBRANE; CANCER INHIBITION; CELL CONTACT; CELL DIFFERENTIATION; CELL LOSS; CELL MOTILITY; CLINICAL TRIAL; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; LYMPHATIC SYSTEM; METASTASIS; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; TUMOR CELL; TUMOR GROWTH;

EID: 0034996039     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1055-3207(18)30072-3     Document Type: Review

References (143)

1. Abe K. Shoji M. Chen J. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor Proc Natl Acad Sci USA 96 1999 8663 8668
2. Achbarou A. Kaiser S. Tremblay G. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo Cancer Res 54 1994 2372 2377
3. Aguirre Ghiso J.A. Kovalski K. Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling J Cell Biol 147 1999 89 104
4. Arras M. Ito W.D. Scholz D. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb J Clin Invest 101 1998 40 50
5. Bacharach E. Itin A. Keshet E. Apposition-dependent induction of plasminogen activator inhibitor type 1 expression: A mechanism for balancing pericellular proteolysis during angiogenesis Blood 92 1998 939 945
6. Bajou K. Noel A. Gerard R.D. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization Nat Med 4 1998 923 928
7. Bastholm L. Increased vascular endothelial growth factor Applied Immunohist Molec Morphol 7 1999 139
8. Behzadian M.A. Wang X.L. Shabrawey M. Effects of hypoxia on glial cell expression of angiogenesis-regulating factors VEGF and TGF-beta Glia 24 1998 216 225
9. Bellocq A. Antoine M. Flahault A. Neutrophil alveolitis in bronchioloalveolar carcinoma: Induction by tumor-derived interleukin-8 and relation to clinical outcome Am J Pathol 152 1998 83 92
10. Bergers G. Javaherian K. Lo K. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice Science 284 1999 808 812
11. Berman M. Winthrop S. Ausprunk D. Plasminogen activator (urokinase) causes vascularization of the cornea Invest Ophthalmol Vis Sci 22 1982 191 199
12. Berse B. Hunt J.A. Diegel R.J. Hypoxia augments cytokine (transforming growth factor-beta (TGF-beta) and interleukin 1 (IL-l)-induced vascular endothelial growth factor secretion by human synovial fibroblasts Clin Exp Immunol 115 1999 176 182
13. Bianchi E. Ferrero E. Fazioli F. Integrin-dependent induction of functional urokinase receptors in primary T lymphocytes J Clin Invest 98 1996 1133 1141
14. Buo L. Meling G.I. Karlsrud T.S. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness Hum Pathol 26 1995 1133 1138
15. Burgle M. Koppitz M. Riemer C. Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides Biol Chem 378 1997 231 237
16. Carriero M.V. Del Vecchio S. Capozzoli M. Urokinase receptor interacts with alpha(v) beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer Cancer Res 59 1999 5307 5314
17. Chiaradonna F. Fontana L. Iavarone C. Urokinase receptor-dependent and -independent p56/59(hck) activation state is a molecular switch between myelomonocytic cell motility and adherence EMBO J 18 1999 3013 3023
18. Cho J.Y. Chung H.C. Noh S.H. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma Cancer 79 1997 878 883
19. Crowley C.W. Cohen R.L. Lucas B.K. Prevention of metastasis by inhibition of the urokinase receptor Proc Natl Acad Sci USA 90 1990 5021 5025
20. de Witte J.H. Sweep C.G. Klijn J.G. Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer Br J Cancer 80 1999 286 294
21. Dell’Era P. Mohammadi M. Presta M. Different tyrosine autophosphorylation requirements in fibroblast growth factor receptor-1 mediate urokinase-type plasminogen activator induction and mitogenesis Mol Biol Cell 10 1999 23 33
22. Dubois-Stringfellow N. Jonczyl-c A. Bautch V.L. Perturbations in the fibrinolytic pathway abolish cyst formation but not capillary-like organization of cultured murine endothelial cells Blood 83 1994 3206 3207
23. Dubuisson L. Monvoisin A. Nielsen B.S. Expression and cellular localization of the urokinase-type plasminogen activator and its receptor in human hepatocellular carcinoma J Pathol 190 2000 190 195
24. Dumler I. Weis A. Mayboroda O.A. The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells J Biol Chem 273 1998 315 321
25. Ellerby H.M. Arap W. Ellerby L.M. Anti-cancer activity of targeted pro-apoptotic peptides Nat Med 5 1999 1032 1038
26. Fibbi G. Caldini R. Chevanne M. Urokinase-dependent angiogenesis in vitro and diacylglycerol production are blocked by antisense oligonucleotides against the urokinase receptor Lab Invest 78 1998 1109 1119
27. Fischer K. Lutz V. Wilhelm O. Urokinase induces proliferation of human ovarian cancer cells: Characterization of structural elements required for growth factor function FEBS Lett 438 1998 101 105
28. Foekens J.A. Peters H.A. Look M.P. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients Cancer Res 60 2000 636 643
29. Folberg R. Hendrix M.J. Maniotis A.J. Vasculogenic mimicry and tumor angiogenesis Am J Pathol 156 2000 361 381
30. Folkman J. Angiogenesis research: From laboratory to clinic Forum (Genova) 9 1999 59 62
31. Franco P. Iaccarino C. Chiaradonna F. Phosphorylation of human pro-urokinase on Serl38/303 impairs its receptor-dependent ability to promote myelomonocytic adherence and motility J Cell Biol 137 1997 779 791
32. Franco P. Iaccarino C. Chiaradonna F. Phosphorylation of human pro-urokinase on Serl38/303 impairs its receptor-dependent ability to promote myelomonocytic adherence and motility J Cell Biol 137 1997 779 791
33. Gamble J.R. Matthias L.J. Meyer G. Regulation of in vitro capillary tube formation by anti-integrin antibodies J Cell Biol 121 1993 931 943
34. Goldfarb R.H. Kitson R.P. Brunson K.W. Biology of cancer metastases. Hematogenous dissemination Lotze M.T. Rubin J.T. Regional Therapy of Advanced Cancer 1997 Lipincott-Raven Philadelphia 1 9
35. Goretzki L. Schmitt M. Mann K. Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L FEBS Lett 297 1992 112 118
36. Graham C.H. Fitzpatrick T.E. McCrae K.R. Hypoxia stimulates urokinase receptor expression through a heme protein-dependent pathway Blood 91 1998 3300 3307
37. Gualandris A. Lopez Conejo T. Giunciuglio D. Urokinase-type plasminogen activator overexpression enhances the invasive capacity of endothelial cells Microvasc Res 53 1997 254 260
38. Guo Y-J Higazi A.A-R Arakelian A. A peptide derived from the non-receptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo FASEB J 14 2000 1400 1410
39. Gupta S.K. Lysko P.G. Pillarisetti K. Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines J Biol Chem 273 1998 4282 4287
40. Hahn-Dantona E. Ramos-DeSimone N. Sipley J. Activation of proMMP-9 by a plasmin/MMP-3 cascade in a tumor cell model. Regulation by tissue inhibitors of metalloproteinases Ann N Y Acad Sci 878 1999 372 387
41. Haj-Yehia A. Nassar T. Sachais B.S. Urokinase-derived peptides regulate vascular smooth muscle contraction in vitro and in vivo FASEB J 14 2000 1411 1422
42. Hanahan D. Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 1996 353 364
43. Higazi A. Cohen R.L. Henkin J. Enhancement of the enzymatic activity of singlechain urokinase plasminogen activator by soluble urokinase receptor J Biol Chem 270 1995 17375 17380
44. Higazi A.A. Mazar A. Wang J. Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1 Blood 87 1996 3545 3549
45. Higazi A A Bdeir K. Hiss E. Lysis of plasma clots by urokinase-soluble urokinase receptor complexes Blood 92 1998 2075 2083
46. Hildenbrand R. Dilger I. Horlin A. Urokinase and macrophages in tumour angiogenesis Br J Cancer 72 1995 818 823
47. Hildenbrand R. Wolf G. Bohme B. Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue J Leukoc Biol 66 1999 40 49
48. Holvoet P. Collen D. Thrombosis and atherosclerosis Curr Opin Lipidol 8 1997 320 328
49. Hsu D.W. Efird J.T. Hedley-Whyte E.T. Prognostic role of urokinase-type plasminogen activator in human gliomas Am J Pathol 147 1995 114 123
50. Ilan N. Mahooti S. Madri J.A. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis J Cell Sci 111 1998 3621 3631
51. Ishikawa H. Satoh H. Kamma H. The effect of TNP-470 on cell proliferation and urokinase-type plasminogen activator and its inhibitor in human lung cancer cell lines J Exp Ther Oncol 1 1996 390 396
52. Ito H. Rovira I.I. Bloom M.L. Endothelial progenitor cells as putative targets for angiostatin Cancer Res 59 1999 5875 5877
53. Jain R.K. Safabakhsh N. Sckell A. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor Proc Natl Acad Sci USA 95 1998 10820 10825
54. Jardi M. Ingles-Esteve J. Burgal M. Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells Thromb Haemost 76 1996 1009 1019
55. Kennedy S. Duffy M.J. Duggan C. Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry Br J Cancer 77 1998 1638 1641
56. 111-165 of vascular endothelial growth factor is critical for its mitogenic potency J Biol Chem 271 1996 7788 7795
57. 3 Int J Cancer 91 2001 300 308
58. Kobayashi H. Schmitt M. Goretzki L. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA) J Biol Chem 266 1991 5147 5152
59. Koivunen E. Arap W. Valtanen H. Tumor targeting with a selective gelatinase inhibitor Nat Biotechnol 17 1999 768 774
60. Konakova M. Hucho F. Schleuning W.D. Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction Eur J Biochem 253 1998 421 429
61. Koshelnick Y. Ehart M. Hufnagl P. Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598 J Biol Chem 272 1997 28563 28567
62. Lang I.M. Moser K.M. Schleef R.R. Elevated expression of urokinase-like plasminogen activator and plasminogen activator inhibitor type 1 during the vascular remodeling associated with pulmonary thromboembolism Arterioscler Thromb Vase Biol 18 1998 808 815
63. Lansink M. Koolwijk P. van Hinsbergh V. Effect of steroid hormones and retinoids on the formation of capillary-like tubular structures of human microvascular endothelial cells in fibrin matrices is related to urokinase expression Blood 92 1998 927 938
64. Li H. Lu H. Griscelli F. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice Gene Ther 5 1998 1105 1113
65. Lu H. Dhanabal M. Volk R. Kringle 5 causes cell cycle arrest and apoptosis of endothelial cells Biochem Biophys Res Commun 258 1999 668 673
66. Lu H. Mabilat C. Yeh P. Blockage of urokinase receptor reduces in vitro the motility and the deformability of endothelial cells FEBS Lett 380 1996 21 24
67. Lucas M.A. Straight D.L. Fretto L.J. The effects of fibrinogen and its cleavage products on the kinetics of plasminogen activation by urokinase and subsequent plasmin activity J Biol Chem 258 1983 12171 12177
68. Marchina E. Barlati S. Degradation of human plasma and extracellular matrix fibronectin by tissue type plasminogen activator and urokinase Int J Biochem Cell Biol 28 1996 1141 1150
69. Lyons R.M. Gentry L.E. Purchio A.F. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin J Cell Biol 110 1990 1361 1367
70. Manchanda N. Schwartz B.S. Single chain urokinase. Augmentation of enzymatic activity upon binding to monocytes J Biol Chem 266 1991 14580 14584
71. Mandriota S.J. Pepper M.S. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor J Cell Sci 110 1997 2293 2302
72. Manes S. Mira E. Gomez-Mouton C. Cells on the move: A dialogue between polarization and motility IUBNB Life 2000 4989 4996
73. Mazzieri R. Masiero L. Zanetta L. Control of type IV collagenase activity by components of the urokinase-plasmin system: A regulatory mechanism with cell-bound reactants EMBO J 16 1997 2319 2332
74. McCourt M. Wang J.H. Sookhai S. Proinflammatory mediators stimulate neutrophil-directed angiogenesis Arch Surg 134 1999 1325 1331 discussion 1331-1332
75. Mechtcheriakova D. Wlachos A. Holzmuller H. Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1 Blood 93 1999 3811 3823
76. Mignatti P. Rifkin D.B. Plasminogen activators and matrix metalloproteinases in angiogenesis Enzyme Prot 49 1996 117 137
77. Min H.Y. Doyle L.V. Vitt C.R. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice Cancer Res 56 1996 2428 2433
78. Mizukami I.F. Garni-Wagner B.A. DeAngelo L.M. 3rd Immunologic detection of the cellular receptor for urokinase plasminogen activator Clin Immunol Immunopathol 71 1994 96 104
79. Mizukami I.F. Todd R.F. 3rd. A soluble form of the urokinase plasminogen activator receptor (suPAR) can bind to hematopoietic cells J Leukoc Biol 64 1998 203 213
80. Mohan P.M. Chintala S.K. Mohanam S. Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth Cancer Res 59 1999 3369 3373
81. Mukhina S. Stepanova V. Traktouev D. The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain; Characterization of interactions and contribution to chemotaxis J Biol Chem 275 2000 16450 16458
82. Murphy G. Stanton H. Cowell S. Mechanisms for pro matrix metalloproteinase activation Apmis 107 1999 38 44
83. Naldini L. Vigna E. Bardelli A. Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction J Biol Chem 270 1995 603 611
84. Nelson A.R. Fingleton B. Rothenberg M.L. Matrix metalloproteinases: Biologic activity and clinical implications J Clin Oncol 18 2000 1135 1149
85. Nguyen D.H. Hussaini I.M. Gonias S.L. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility J Biol Chem 273 1998 8502 8507
86. Nip J. Rabbani S.A. Shibata H.R. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells J Clin Invest 95 1995 2096 20103
87. Nykjaer A. Conese M. Christensen E.I. Recycling of the urokinase receptor upon internalization of the uPA: Serpin complexes EMBO J 16 1997 2610 2620
88. O’Mahony C.A. Albo D. Tuszynski G.P. Transforming growth factor-beta 1 inhibits generation of angiostatin by human pancreatic cancer cells Surgery 124 1998 388 393
89. Odekon L.E. Sato Y. Rifkin D.B. Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity J Cell Physiol 150 1992 258 263
90. Ohtani H. Pyke C. Dano K. Expression of urokinase receptor in various stromalcell populations in human colon cancer: Immunoelectron microscopical analysis Int J Cancer 62 1995 691 696
91. Ohtani H. Stromal reaction in cancer tissue: Pathophysiologic significance of the expression of matrix-degrading enzymes in relation to matrix turnover and immune/inflammatory reactions Pathol Int 48 1998 1 9
92. Park J.E. Keller G.A. Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF Mol Biol Cell 4 1993 1317 1326
93. Patterson B.C. Sang Q.A. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9) J Biol Chem 272 1997 28823 28825
94. Pepper M.S. Mandriota S.J. Jeltsch M. Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity J Cell Physiol 177 1998 43 452
95. Pepper M.S. Montesano R. Mandriota S.J. Angiogenesis: A paradigm for balanced extracellular proteolysis during cell migration and morphogenesis Enzyme Protein 49 1996 138 162
96. Pinsky D.J. Liao H. Lawson C.A. Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition J Clin Invest 102 1998 919 928
97. Planus E. Barlovatz-Meimon G. Rogers R.A. Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading J Cell Sci 110 1997 1091 1098
98. Proescholdt M.A. Heiss J.D. Walbridge S. Vascular endothelial growth factor (VEGF) modulates vascular permeability and inflammation in rat brain J Neuropathol Exp Neurol 58 1999 613 627
99. Qi J. Kreutzer D.L. Piela-Smith T.H. Fibrin induction of ICAM-1 expression in human vascular endothelial cells J Immunol 158 1997 1880 1886
100. Rabbani S.A. Xing R.H. Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies Int J Oncol 12 1998 911 920
101. Rabbani S.A. Desjardins J. Bell A.W. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells Biochem Biophys Res Commun 173 1990 1058 1064
102. Rabbani S.A. Gladu J. Mazar A.P. Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase J Cell Physiol 172 1997 137 145
103. Rabbani S.A. Urokinase receptor directed immunodiagnostic and immunotherapeutic strategies for prostate and breast Cancer Proc Am Assoc Cancer Res 38 1997 A1673
104. Ramsby M.L. Kreutzer D.L. Fibrin induction of interleukin-8 expression in corneal endothelial cells in vitro Invest Ophthalmol Vis Sci 35 1994 3980 3990
105. Ray J.M. Stetler-Stevenson W.G. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis Eur Respir J 7 1994 2062 2072
106. Remacle-Bonnet M.M. Garrouste F.L. Pommier G.J. Surface-bound plasmin induces selective proteolysis of insulin-like-growth-factor (IGF)-binding protein-4 (IGFBP-4) and promotes autocrine IGF-II bio-availability in human colon-carcinoma cells Int J Cancer 72 1997 835 843
107. Ribatti D. Leali D. Vacca A. In vivo angiogenic activity of urokinase: Role of endogenous fibroblast growth factor-2 J Cell Sci 112 1999 4213 4221
108. Ried S. Jager C. Jeffers M. Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor J Biol Chem 274 1999 16377 16386
109. Rogers C. Edelman E.R. Simon D.I. A mAb to the beta2-leukocyte integrin Mac-1 (CDllb/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits Proc Natl Acad Sci USA 95 1998 10134 10139
110. Rosenthal E.L. Johnson T.M. Allen E.D. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells Cancer Res 58 1998 5221 5230
111. /-dimycolate (Cord factor) enhances neovascularization through vascular endothelial growth factor production by neutrophils and macrophages Infect Immun 68 2000 2043 2052
112. Saksela O. Plasminogen activation and regulation of pericellular proteolysis Biochim Biophys Acta 823 1985 35 65
113. Schnaper H.W. Barnathan E.S. Mazar A. Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways J Cell Physiol 165 1995 107 118
114. Schneller M. Vuori K. Ruoslahti E. Alphavbeta3 integrin associates with activated insulin and PDGFbeta receptors and potentiates the biological activity of PDGF EMBO J 16 1997 5600 5607
115. Sendo F. Suzuki K. Watanabe T. Modulation of leukocyte transendothelial migration by integrin-associated glycosyl phosphatidyl inositol (GPI)-anchored proteins Inflamm Res 47 1998 133 136
116. Simon D.I. Wei Y. Zhang L. Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function [In Process Citation] J Biol Chem 275 2000 10228 10234
117. Stack M.S. Johnson D.A. Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase) J Biol Chem 269 1994 9416 9419
118. Stathakis P. Lay A.J. Fitzgerald M. Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin J Biol Chem 274 1999 8910 8916
119. Stephens R.W. Brunner N. Janicke F. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer Breast Cancer Res Treat 52 1998 99 111
120. Strojan P. Budihna M. Smid L. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients Eur J Cancer 34 1998 1193 1197
121. Stonelake P.S. Jones C.E. Neoptolemos J.P. Proteinase inhibitors reduce basement membrane degradation by human breast cancer cell lines Br J Cancer 75 1997 9515 9519
122. Tanaka K. Abe M. Sato Y. Roles of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase in the signal transduction of basic fibroblast growth factor in endothelial cells during angiogenesis Jpn J Cancer Res 90 1999 647 654
123. Tang H. Kerins D.M. Hao Q. The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells J Biol Chem 273 1998 8268 8272
124. Taniguchi T. Kakkar A.K. Tuddenham E.G. Enhanced expression of urokinase receptor induced through the tissue factor-factor Vila pathway in human pancreatic cancer Cancer Res 58 1998 4461 4467
125. Torisu H. Ono M. Kiryu H. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: Possible involvement of TNFalpha and IL-lalpha Int J Cancer 85 2000 182 188
126. van Leeuwen R.L. Yoshinaga I.G. Akasaka T. Attachment, spreading and migration of melanoma cells on vitronectin. The role of alpha V beta 3 and alpha V beta 5 integrins Exp Dermatol 5 1996 308 315
127. van Hinsbergh V.W. Koolwijk P. Hanemaaijer R. Role of fibrin and plasminogen activators in repair-associated angiogenesis: In vitro studies with human endothelial cells Exs 79 1997 391 411
128. Waltz D.A. Fujita R.M. Yang X. Nonproteolytic role for the urokinase receptor in cellular migration in vivo Am J Respir Cell Mol Biol 22 2000 316 322
129. Webb C.P. Hose C.D. Koochekpour S. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network Cancer Res 60 2000 342 349
130. Webb D.J. Nguyen D.H. Gonias S.L. Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and matrigel invasion J Cell Sci 113 2000 123 134
131. Wei Y. Yang X. Liu Q. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling J Cell Biol 144 1999 1285 1294
132. Wilcox S.A. Reho T. Higgins P.J. Localization of urokinase to focal adhesions by human fibrosarcoma cells synthesizing recombinant vitronectin Biochem Cell Biol 74 1996 899810
133. Wong W.S. Simon D.I. Rosoff P.M. Mechanisms of pertussis toxin-induced myelomonocytic cell adhesion: Role of Mac-1 (CDllb/CD18) and urokinase receptor (CD87) Immunol 88 1996 90 97
134. Wood J.M. Bold G. Buchdunger E. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. [In Process Citation] Cancer Res 60 2000 2178 2189
135. Xing R.H. Mazar A. Henkin J. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428 Cancer Res 57 1997 3585 3593
136. Xing R.H. Rabbani S.A. Regulation of urokinase production by androgens in human prostate cancer cells: Effect on tumor growth and metastases in vivo Endocrinology 140 1999 4056 4064
137. Xu Y. Hagege J. Doublet J.D. Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma Hum Pathol 28 1997 206 213
138. Xue W. Mizukami I. Todd R.F. 3rd. Urokinase-type plasminogen activator receptors associate with betal and beta3 integrins of fibrosarcoma cells: Dependence on extracellular matrix components Cancer Res 57 1997 1682 1689
139. Yamamoto M. Sawaya R. Mohanam S. Expression and localization of urokinase-type plasminogen activator receptor in human gliomas Cancer Res 54 1994 5016 5020
140. Yebra M. Goretzki L. Pfeifer M. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by ei^hancing integrin-mediated signal transduction Exp Cell Res 250 1999 231 240
141. Yebra M. Parry G.C.N. Stromblad S. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration J Biol Chem 271 1996 29393 29399
142. Zanetti A. Stoppacciaro A. Marzullo A. Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid J Pathol 186 1998 287 291
143. Zhang J.C. Sakthivel R. Kniss D. The low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor regulates cell surface plasminogen activator activity on human trophoblast cells J Biol Chem 273 1998 32273 32280